SQZ-PDX1-101

**SQZ-PDX1-101** is an investigational cell therapy developed by SQZ Biotechnologies using proprietary microfluidic squeezing technology to engineer patient-derived peripheral blood mononuclear cells (PBMCs) or antigen-presenting cells loaded with antigens targeting PDX1, a transcription factor overexpressed in pancreatic ductal adenocarcinoma (PDAC) and implicated in tumorigenesis. It aims to stimulate antigen-specific T-cell responses for antitumor immunity, potentially as a personalized cancer vaccine. While preclinical data support PDX1 inhibition for PDAC via RNAi or gene therapy, clinical development status for SQZ-PDX1-101 remains unclear, distinguishing it from SQZ's HPV-targeted programs like SQZ-PBMC-HPV-101.